January 15th, 2008
The thiazolidinediones rosiglitazone and pioglitazone are peroxisome proliferator-activated receptor-γ agonists, with insulin-sensitizing properties, used in the treatment of Type 2 diabetes. The oral bioavailability of rosiglitazone is nearly 100% and that of pioglitazone >80%. Both drugs are extensively metabolized in the liver. Rosiglitazone is mainly biotransformed by N-demethylation and pyridine ring hydroxylation and pioglitazone by [...]
Filed under: Pharmacogenetics | No Comments »
January 15th, 2008
Treatment of inflammatory bowel disease (IBD) is currently based on aminosalicylates, corticosteroids, immunosuppressives, biologicals, antibiotics, nutritional support and surgery. These therapies are limited by side-effects and may be inefficient in up to 30% of patients. Steroid-refractory and steroid-dependent patients are at great risk of extensive bowel resections, even though surgery cannot cure IBD. These patients [...]
Filed under: Pharmacogenetics | No Comments »
January 15th, 2008
Antilymphocyte globulins (ALGs) are polyclonal antibodies used in organ transplantation to prevent or treat acute allograft rejection. ALGs are obtained by immunizing animals (rabbits or horses) with human lymphoid cells (lymphoblasts, lymphocytes or thymocytes). Although ALGs have been in use for several decades, the interindividual variability in patient response remains poorly understood. Monitoring of drug [...]
Filed under: Pharmacogenetics | No Comments »